Diagnostic products that KidsDx will commercialize will use different proprietary algorithms on the client blood samples to provide an easily interpretable “Risk Score” or a “Likelihood score” and an associated statistical significance. Tests include, but are not limited to:
Risk Prediction of Autism: This test will consist of biomarkers that predict the onset of Autism before the complete presentation of reportable clinical symptoms (<2yrs).
Differential Diagnosis: This consists of a menu of 8 tests which differentiate Autism Cluster Phenotypes from non-ASD associated co-morbid conditions—at once or sequentially.
Therapeutic Selection: This consists of a menu of 10 tests which differentiate the best therapeutic considerations in addition to alternative treatment or behavioral intervention options for a patient with ASD.
Therapy Monitoring: Ongoing tests for monitoring up to 30 different treatment or behavioral intervention options.
KidsDx has developed a proprietary Knowledge Discovery platform, KDDxTM, that unifies our domain expertise in computational proteomics with cellular networks, system networks, and molecular networks to generate actionable clinical intelligence focused on the discovery and development of blood based diagnostics with broader implications towards treatment intervention strategies.
